BORA PHARMACEUTICALS LTD (6472) — Capital Reinvestment Ratio
Latest as of March 2026:
0.37x
BORA PHARMACEUTICALS LTD (6472) has a Capital Reinvestment Ratio of 0.37x as of March 2026, meaning it reinvests 0% of its operating cash flow (NT$568.46 Million) in capital expenditures (NT$211.08 Million). See BORA PHARMACEUTICALS LTD free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.37x
Capex / Operating Cash Flow
Operating Cash Flow
NT$568.46 Million
TWD
Capital Expenditures
NT$211.08 Million
TWD
Data as of
Mar 2026
Most recent filing
BORA PHARMACEUTICALS LTD Capital Reinvestment Ratio (2019–2025)
This chart tracks BORA PHARMACEUTICALS LTD's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for BORA PHARMACEUTICALS LTD (2019–2025)
Year-by-year Capital Reinvestment Ratio for BORA PHARMACEUTICALS LTD from 2019 to 2025. For live market cap and broader valuation context, see BORA PHARMACEUTICALS LTD market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | NT$4.24 Billion | NT$928.67 Million | ▼ -68.7% |
| 2024 | 0.70x | NT$980.81 Million | NT$687.05 Million | ▲ +126.0% |
| 2023 | 0.31x | NT$4.61 Billion | NT$1.43 Billion | ▲ +211.2% |
| 2022 | 0.10x | NT$2.01 Billion | NT$200.22 Million | ▼ -66.1% |
| 2021 | 0.29x | NT$1.24 Billion | NT$363.58 Million | ▼ -65.6% |
| 2020 | 0.86x | NT$177.79 Million | NT$152.09 Million | ▼ -71.6% |
| 2019 | 3.01x | NT$231.77 Million | NT$697.33 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow